A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) - Trial NCT05818137
Access comprehensive clinical trial information for NCT05818137 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp & Dohme LLC and is currently Recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 35 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Merck Sharp & Dohme LLC
Timeline & Enrollment
Phase 3
May 10, 2023
Jul 24, 2026
Primary Outcome
Change from Pulmonary Vascular Resistance (PVR) from Baseline at Week 24,Number of Participants experiencing Adverse Events (AEs),Number of Participants who Discontinue Study Intervention due to AEs
Summary
This local Phase 3 study is planned to confirm the efficacy and safety in Japanese PAH
 participants. The primary population of this study is Japanese PAH participants with World
 Health Organization Functional Class (WHO FC) II or III while the study includes PAH
 participants with WHO FC I or IV as other populations. There are no hypotheses for this
 study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05818137
Non-Device Trial